Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
Sponsor: Tang Yida
Summary
The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).
Official title: Efficacy and Safety of Berberine on Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome: a Randomized, Controlled Trial
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
5200
Start Date
2021-12
Completion Date
2028-12
Last Updated
2021-11-03
Healthy Volunteers
No
Conditions
Interventions
Berberine
The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
Healthy lifestyle intervention
Healthy lifestyle intervention will be launched according to the "Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019", including health lectures, health information promotion, health manual and so on.
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China